Postoperative Management of Differentiated Thyroid Cancer

[1]  E. Sturgis,et al.  Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. , 2018, Thyroid : official journal of the American Thyroid Association.

[2]  S. Filetti,et al.  Follow-up of differentiated thyroid cancer – what should (and what should not) be done , 2018, Nature Reviews Endocrinology.

[3]  M. A. van den Bosch,et al.  Radioembolisation in Europe: A Survey Amongst CIRSE Members , 2018, CardioVascular and Interventional Radiology.

[4]  T. Montesano,et al.  8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2). , 2017, Endocrine-related cancer.

[5]  D. Filippiadis,et al.  Pain management: The rising role of interventional oncology. , 2017, Diagnostic and interventional imaging.

[6]  Jee Soo Kim,et al.  Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma. , 2017, Oral oncology.

[7]  B. Hankey,et al.  Increases in Thyroid Cancer Incidence and Mortality. , 2017, JAMA.

[8]  O. Mundler,et al.  Incidence of salivary side effects after radioiodine treatment using a new specifically-designed questionnaire. , 2017, The British journal of oral & maxillofacial surgery.

[9]  S. Larson,et al.  Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry–Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer , 2017, The Journal of Nuclear Medicine.

[10]  A. Sahgal,et al.  Initial single center experience: radiofrequency ablation assisted vertebroplasty and osteoplasty using a bipolar device in the palliation of bone metastases. , 2017, Annals of palliative medicine.

[11]  Martyn Plummer,et al.  Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. , 2016, The New England journal of medicine.

[12]  E. Genden,et al.  External‐beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society , 2016, Head & neck.

[13]  J. Joo,et al.  Percutaneous vertebroplasty for patients with metastatic compression fractures of the thoracolumbar spine: clinical and radiological factors affecting functional outcomes. , 2016, The spine journal : official journal of the North American Spine Society.

[14]  Sung-Bae Kim,et al.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.

[15]  R. Paschke,et al.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.

[16]  M. Brose,et al.  Management of sorafenib-related adverse events: a clinician's perspective. , 2014, Seminars in oncology.

[17]  P. Giannoudis,et al.  Spinal metastasis in thyroid cancer , 2012, Head & neck oncology.

[18]  M. Schlumberger,et al.  Strategies of radioiodine ablation in patients with low-risk thyroid cancer. , 2012, The New England journal of medicine.

[19]  J. Wexler.  Approach to the thyroid cancer patient with bone metastases. , 2011, The Journal of clinical endocrinology and metabolism.

[20]  M. Schlumberger,et al.  Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. , 2011, The Journal of clinical endocrinology and metabolism.

[21]  D. Nostrand.  Sialoadenitis secondary to ¹³¹I therapy for well-differentiated thyroid cancer. , 2011 .

[22]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[23]  M. Schlumberger,et al.  Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. , 2009, Thyroid : official journal of the American Thyroid Association.

[24]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[25]  R. Wahl,et al.  Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. , 2009, The Journal of clinical endocrinology and metabolism.

[26]  T. Sebo,et al.  Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. , 2008, Surgery.

[27]  A. Hackshaw,et al.  The HiLo trial: a multicentre randomised trial of high- versus low-dose radioiodine, with or without recombinant human thyroid stimulating hormone, for remnant ablation after surgery for differentiated thyroid cancer. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[28]  P. Ladenson,et al.  The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[29]  George Sgouros,et al.  Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  R. Tsang,et al.  Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years , 2005, Clinical endocrinology.

[31]  H. Boezen,et al.  Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. , 2005, Endocrine-related cancer.

[32]  W W Mayo-Smith,et al.  Radiofrequency ablation of bony metastatic disease. , 2004, Clinical radiology.

[33]  A. Shaha.  Implications of Prognostic Factors and Risk Groups in the Management of Differentiated Thyroid Cancer , 2004, The Laryngoscope.

[34]  S. Mandel,et al.  Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.

[35]  R. Kloos,et al.  Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. , 2002, The Journal of clinical endocrinology and metabolism.

[36]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[37]  M. Ringel,et al.  Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. , 2001, The Journal of clinical endocrinology and metabolism.

[38]  R. Solans,et al.  Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  Macp,et al.  Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[40]  T. Guise,et al.  Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. , 1999, The Journal of clinical endocrinology and metabolism.

[41]  O. Ozaki,et al.  Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. , 1999, The Journal of clinical endocrinology and metabolism.

[42]  C. Kirsch,et al.  Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  S. Roman,et al.  Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines? , 2018, Surgery.

[44]  Nancy D Perrier,et al.  Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2018, CA: a cancer journal for clinicians.

[45]  E. Baudin,et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[46]  J. Romijn,et al.  Survival and death causes in differentiated thyroid carcinoma. , 2006, The Journal of clinical endocrinology and metabolism.